Hims & Hers Drops Plan for Wegovy Knockoff Amid FDA Crackdown

Telehealth company reverses course after Novo Nordisk threatens legal action over copycat weight loss pill

Published on Feb. 7, 2026

Got story updates? Submit your updates here. ›

Telehealth company Hims & Hers has dropped its plan to offer a compounded version of the weight-loss drug Wegovy, just days after announcing the new product. The decision comes after Novo Nordisk, the maker of Wegovy, threatened legal action and the FDA said it would take steps to limit access to the active ingredients used in popular GLP-1 weight loss medications.

Why it matters

The Wegovy drug has seen booming demand, prompting companies like Hims to try and capitalize on the multibillion-dollar weight loss medication market by offering cheaper, unapproved versions. However, the FDA and pharmaceutical companies are cracking down on these copycat products to protect their investments in developing and testing new weight loss treatments.

The details

Hims had announced on Thursday that it would sell a compounded version of Wegovy for $49 per month, significantly undercutting Novo Nordisk's $149 per month price. But Novo immediately threatened to sue, and the FDA then said it would take steps to limit access to the active ingredients used in GLP-1 drugs like Wegovy. As a result, Hims has now reversed course and will no longer offer the unapproved Wegovy copycat.

  • On February 6, 2026, Hims announced plans to sell a compounded version of the Wegovy weight loss pill.
  • On February 7, 2026, Novo Nordisk threatened legal action against Hims over the copycat drug.
  • On February 8, 2026, the FDA said it would take steps to restrict access to the active ingredients used in GLP-1 weight loss medications.
  • Also on February 8, 2026, Hims announced it was dropping plans to sell the compounded Wegovy drug.

The players

Hims & Hers

A telehealth company that had planned to offer a compounded version of the Wegovy weight loss pill at a lower price than the original.

Novo Nordisk

The Danish pharmaceutical company that manufactures the FDA-approved Wegovy weight loss medication.

U.S. Food and Drug Administration (FDA)

The federal agency that regulates and oversees the approval of drugs in the United States, and which announced plans to restrict access to the active ingredients used in GLP-1 weight loss drugs.

Got photos? Submit your photos here. ›

What they’re saying

“Since launching the compounded semaglutide pill on our platform, we've had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment.”

— Hims & Hers (X)

What’s next

The FDA is expected to take further action to limit access to the active ingredients used in GLP-1 weight loss drugs like Wegovy, which could impact other companies offering unapproved copycat versions of these medications.

The takeaway

This case highlights the tension between patient demand for affordable weight loss treatments and the pharmaceutical industry's efforts to protect its investments in developing and testing new drugs. The FDA is stepping in to enforce regulations around unapproved copycat medications, even as telehealth companies seek to capitalize on the booming market for weight loss drugs.